et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7) (Peer Reviewed)
Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose ivermectin patients and 12 control patients, showing significantly faster viral load reduction and symptom improvement with ivermectin.
Average median viral load for gene E and gene N mid-viral recovery at day 7:
Probability of symptoms at day 28, adjusted for the time since onset and day of followup:
Ivermectin: = 0.26 [0.10-0.42]
control: 0.55 [0.33-0.77]
(details are in the supplementary appendix)
Chaccour et al., 12/7/2020, Double Blind Randomized Controlled Trial, Spain, Europe, peer-reviewed, 23 authors, dosage 400μg/kg single dose.
risk of unresolved symptoms, 52.9% lower, RR 0.47, p < 0.05, treatment 12, control 12, relative probability of symptoms at day 28.
viral load, 94.6% lower, relative load 0.05, treatment 12, control 12, day 7 mid-recovery.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of